Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SHR-A2009 versus platinum-based chemotherapy in EGFR-mutant advanced or metastatic non-squamous non-small cell lung cancer after EGFR TKI failure
CTR20244118Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ruzaltatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Dec 2024; status: active.
02
Drugs
ruzaltatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244118.